Table 2. Number and proportion of off-label prescriptions stratified by off-label type (year 2008).
| Compound class | Compound | All prescriptions (n) | Off-label overall (n,%) | Off-label due to age only (n) | Off-label due to indication only (n) | Off-label due to age and indication (n) |
| Inhaled SABA | Salbutamol | 159,655 | 67,084 (42.0%) | 0 | 67,084 | 0 |
| Fenoterol | 1,452 | 383 (26.4%) | 6 | 367 | 10 | |
| Terbutaline | 184 | 34 (18.5%) | 0 | 33 | 1 | |
| Inhaled SABA combination | Fenoterol/Ipratropium (fixed combination) | 3,998 | 1,722 (43.1%) | 0 | 1,722 | 0 |
| Reproterol/CGA (fixed combination) | 8,729 | 2,538 (29.1%) | 0 | 2,538 | 0 | |
| Inhaled SABA (incl. combination) Total | 174,018 | 71,761 (41.2%) | 6 | 71,744 | 11 | |
| Inhaled LABA | Salmeterol | 522 | 86 (16.5%) | 9 | 75 | 2 |
| Formoterol | 4,931 | 839 (17.0%) | 88 | 730 | 21 | |
| Inhaled LABA/ICS | Salmeterol/Fluticasone (fixed combination) | 27,600 | 4,278 (15.5%) | 368 | 3,734 | 176 |
| Formoterol/Beclomethasone (fixed combination) | 2,515 | 848 (33.7%) | 11 | 827 | 10 | |
| Formoterol/Budesonide (fixed combination) | 13,833 | 2,584 (18.7%) | 113 | 2,412 | 59 | |
| Inhaled LABA (incl. combination) Total | 49,401 | 8,635 (17.5%) | 589 | 7,778 | 268 | |
| SAMA | Ipratropium | 21,822 | 10,910 (50.0%) | 0 | 10,910 | 0 |
| LAMA | Tiotropium | 97 | 96 (99.0%) | 9 | 11 | 76 |
| Muscarinic antagonists (SAMA & LAMA) Total | 21,919 | 11,006 (50.2%) | 9 | 10,921 | 76 | |
| Inhaled bronchodilative drugs (SABA, LABA, SAMA, LAMA [incl. combination]) Total | 245,338 | 91,402 (37.3%) | 604 | 90,443 | 355 | |
| ICS | Budesonide | 42,067 | 3,166 (7.5%) | 0 | 3,166 | 0 |
| Beclomethasone | 24,185 | 1,922 (7.9%) | 0 | 1,922 | 0 | |
| Fluticasone | 17,097 | 5,360 (31.4%) | 1,917 | 2,370 | 1,073 | |
| Ciclesonide | 326 | 110 (33.7%) | 35 | 60 | 15 | |
| ICS total | 83,675 | 10,558 (12.6%) | 1,952 | 7,518 | 1,088 | |
| Oral B2A | Salbutamol | 19,475 | 5,544 (28.5%) | 0 | 5,544 | 0 |
| Terbutaline | 6,940 | 2,012 (29.0%) | 0 | 2,012 | 0 | |
| Tulobuterol | 1,201 | 330 (27.5%) | 32 | 292 | 6 | |
| Clenbuterol | 113 | 67 (59.3%) | 0 | 67 | 0 | |
| Oral B2A combination | Clenbuterol/Ambroxol (fixed combination) | 91,385 | 18,897 (20.7%) | 0 | 18,897 | 0 |
| Oral B2A (incl. combination) total | 119,114 | 26,850 (22.5%) | 32 | 26,812 | 6 | |
| Others | Theophylline | 1,184 | 451 (38.1%) | 7 | 419 | 25 |
| Montelukast | 33,501 | 12,826 (38.3%) | 304 | 11,831 | 691 | |
| Cromoglicic acid | 5,087 | 3,247 (63.8%) | 110 | 2,724 | 413 | |
| Others Total | 39,772 | 16,524 (41.5%) | 421 | 14,974 | 1,129 | |
| All drugs Total | 487,899 | 145,334 (29.8%) | 3,009 | 139,747 | 2,578 | |
SABA: Short-acting beta-2-agonist, CGA: Cromoglicic acid, LABA: Long-acting beta-2-agonist, ICS: Inhaled corticosteroid, SAMA: Short-acting muscarinic antagonist, LAMA: Long-acting muscarinic antagonist, B2A: Beta-2-agonist.